Drugs / Lenacapavir pacfosacil
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06613685 | Oct 2024 → Mar 2026 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT06544733 | Aug 2024 → Jan 2028 expected | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lenacapavir pacfosacil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06613685 ↗ |
| Route | Oral | “Tablets administered orally without regard to food” NCT06613685 ↗ |